Frazier Life Sciences Management L.P. Takes Position in Zai Lab Limited Unsponsored ADR $ZLAB

Key Points

• Frazier Life Sciences Management L.P. purchased 350,000 shares of Zai Lab Limited, valued at approximately $12.6 million, marking a 0.32% ownership stake in the company.
• Zai Lab's stock has recently seen a trading increase of 2.7%, currently valued at $33.10 per share with a market cap of $3.70 billion.
• Equities analysts have given Zai Lab a consensus rating of "Moderate Buy" with an average price target of $56.35.

Frazier Life Sciences Management L.P. acquired a new position in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 350,000 shares of the company's stock, valued at approximately $12,649,000. Frazier Life Sciences Management L.P. owned approximately 0.32% of Zai Lab as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. purchased a new stake in shares of Zai Lab during the 4th quarter valued at approximately $29,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Zai Lab during the 1st quarter valued at $75,000. Advisors Preferred LLC bought a new position in shares of Zai Lab during the 1st quarter valued at $110,000. Barclays PLC grew its holdings in shares of Zai Lab by 337.6% during the 4th quarter. Barclays PLC now owns 3,702 shares of the company's stock valued at $97,000 after purchasing an additional 2,856 shares during the last quarter. Finally, Palumbo Wealth Management LLC bought a new position in shares of Zai Lab during the 1st quarter valued at $203,000. 41.65% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Ying Du sold 46,387 shares of the stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $35.47, for a total value of $1,645,346.89. Following the completion of the transaction, the chief executive officer directly owned 536,962 shares of the company's stock, valued at $19,046,042.14. This trade represents a 7.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Joshua L. Smiley sold 6,641 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $36.24, for a total transaction of $240,669.84. Following the transaction, the insider directly owned 76,604 shares of the company's stock, valued at $2,776,128.96. This represents a 7.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 215,710 shares of company stock valued at $7,589,684. Corporate insiders own 4.96% of the company's stock.

Zai Lab Price Performance

Shares of ZLAB stock traded up $0.76 during mid-day trading on Friday, hitting $30.76. The company had a trading volume of 925,957 shares, compared to its average volume of 489,351. Zai Lab Limited Unsponsored ADR has a 52-week low of $19.16 and a 52-week high of $44.34. The stock's 50 day moving average price is $35.22 and its 200-day moving average price is $34.07. The company has a market capitalization of $3.44 billion, a P/E ratio of -15.08 and a beta of 1.04.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.37) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.37). The business had revenue of $109.98 million for the quarter, compared to analysts' expectations of $125.66 million. Zai Lab had a negative net margin of 49.68% and a negative return on equity of 27.32%. Zai Lab has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Wall Street Zen lowered shares of Zai Lab from a "buy" rating to a "hold" rating in a report on Friday, June 27th. Leerink Partners set a $75.00 price target on shares of Zai Lab and gave the stock an "outperform" rating in a report on Monday, June 30th. Citigroup reissued a "buy" rating and issued a $69.00 price target (up previously from $66.00) on shares of Zai Lab in a report on Monday, August 11th. Finally, Jefferies Financial Group assumed coverage on shares of Zai Lab in a report on Monday, August 25th. They issued a "buy" rating and a $52.00 price target on the stock. Six investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Zai Lab currently has a consensus rating of "Moderate Buy" and an average price target of $56.35.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.